Free Trial

Alzamend Neuro (ALZN) News Today

→ Don’t make this retirement mistake (From Sasco Gold LLC) (Ad)
Free ALZN Stock Alerts
$0.56
-0.02 (-3.45%)
(As of 06/10/2024 ET)
Compare
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends
May 9, 2024 | finance.yahoo.com
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 9, 2024 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
May 7, 2024 | msn.com
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
May 7, 2024 | finance.yahoo.com
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
April 24, 2024 | msn.com
Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying
April 17, 2024 | msn.com
Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42
March 26, 2024 | msn.com
ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024
February 24, 2024 | msn.com
Alzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50
February 13, 2024 | realmoney.thestreet.com
Maxim gets more bearish on Alzamend Neuro, downgrades shares
February 3, 2024 | msn.com
Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency
December 19, 2023 | markets.businessinsider.com
Buy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market Potential
December 18, 2023 | msn.com
ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024
December 18, 2023 | msn.com
ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024
December 11, 2023 | finance.yahoo.com
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
December 11, 2023 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
November 20, 2023 | marketwatch.com
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment
November 20, 2023 | msn.com
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
November 20, 2023 | finance.yahoo.com
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
November 16, 2023 | finance.yahoo.com
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
November 13, 2023 | msn.com
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
November 13, 2023 | finance.yahoo.com
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
November 2, 2023 | msn.com
Alzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38
October 30, 2023 | benzinga.com
Why Alzamend Neuro (ALZN) Stock Is Nosediving Today
October 30, 2023 | finance.yahoo.com
Alzamend Neuro Announces Reverse Stock Split
October 25, 2023 | finance.yahoo.com
Alzamend Neuro, Inc. (9ZT0.F)
October 23, 2023 | businesswire.com
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
October 2, 2023 | msn.com
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
October 2, 2023 | finance.yahoo.com
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
September 27, 2023 | seekingalpha.com
Alzamend Neuro CFO Katzoff buys 53K shares
September 26, 2023 | yahoo.com
Rep. Jennifer Wexton Will Not Run for Re-Election After Rare Neurological Disorder Diagnosis
September 22, 2023 | finance.yahoo.com
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
August 30, 2023 | msn.com
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
August 30, 2023 | finance.yahoo.com
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
August 25, 2023 | benzinga.com
Benzinga Neuro
August 24, 2023 | finance.yahoo.com
We're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
June 28, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)
June 24, 2023 | morningstar.com
Alzamend Neuro Inc Ordinary Shares
June 22, 2023 | finance.yahoo.com
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
June 22, 2023 | benzinga.com
EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
June 13, 2023 | finance.yahoo.com
Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group’s Virtual Healthcare Conference
April 14, 2023 | benzinga.com
Alzamend Neuro Stock (NASDAQ:ALZN), Dividends
April 12, 2023 | msn.com
Maxim Group Initiates Coverage of Alzamend Neuro (ALZN) with Buy Recommendation
April 3, 2023 | finance.yahoo.com
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 3, 2023 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine
April 3, 2023 | finance.yahoo.com
KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
March 22, 2023 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
March 17, 2023 | finance.yahoo.com
We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully
March 16, 2023 | finance.yahoo.com
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
February 21, 2023 | barrons.com
Alzamend Neuro Inc.
January 26, 2023 | finance.yahoo.com
Alzamend Neuro to Present at Sequire Biotechnology Conference
Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.

Don’t make this retirement mistake (Ad)

If you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it.

Reserve your seat here.

ALZN Media Mentions By Week

ALZN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALZN
News Sentiment
▼
0.00

0.76
▲
Average
Medical
News Sentiment

ALZN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALZN Articles
This Week
▼
0

0
▲
ALZN Articles
Average Week

Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ALZN) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
DON’T buy gold until you read this
If you're an American who understands that your money is rotting away as you read this email… Then this is ...
Sasco Gold LLC | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Hurry! Buy this stock before the Robinhood traders do!
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...
Traders Agency | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored